The FLT3 inhibitor midostaurin, the antibody-drug conjugate gemtuzumab 
ozogamicin, CPX-351 (liposomal daunorubicin and cytarabine), and the IDH2 
inhibitor enasidenib are among the novel agents approved for use in the clinic 
this past year. This year, 2018, already has seen the regulatory approval of the 
BCL2 inhibitor venetoclax in the form of breakthrough designation and the IDH1 
inhibitor ivosidenib received full FDA approval. Much remains to be learned 
about how best to use these drugs to improve patient outcomes and how best to 
employ and interpret next-generation sequencing to determine measurable residual 
disease (MRD) levels that can more accurately predict risk of relapse.